|Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.|
Wei, C; Cao, Y; Yang, X; Zheng, Z; Guan, K; Wang, Q; Tai, Y; Zhang, Y; Ma, S; Cao, Y; Ge, X; Xu, C; Li, J; Yan, H; Ling, Y; Song, T; Zhu, L; Zhang, B; Xu, Q; Hu, C; Bian, XW; He, X; Zhong, H
Proceedings of the National Academy of Sciences of the United States of America
Resistance to antiestrogens is one of the major challenges in breast cancer treatment. Although phosphorylation of estrogen receptor α (ERα) is an important factor in endocrine resistance, the contributions of specific kinases in endocrine resistance are still not fully understood. Here, we report that an important innate immune response kinase, the IκB kinase-related TANK-binding kinase 1 (TBK1), is a crucial determinant of resistance to tamoxifen therapies. We show that TBK1 increases ERα transcriptional activity through phosphorylation modification of ERα at the Ser-305 site. Ectopic TBK1 expression impairs the responsiveness of breast cancer cells to tamoxifen. By studying the specimens from patients with breast cancer, we find a strong positive correlation of TBK1 with ERα, ERα Ser-305, and cyclin D1. Notably, patients with tumors highly expressing TBK1 respond poorly to tamoxifen treatment and show high potential for relapse. Therefore, our findings suggest that TBK1 contributes to tamoxifen resistance in breast cancer via phosphorylation modification of ERα.